S100a9 was highly expressed in lower-risk MDS, which presented as ineffective hematopoiesis, leading to peripheral cytopenia, and expressed at low levels in higher-risk MDS, which was characterized by AML progression. Here, S100A9 is linked to acute myeloid leukemia.